Preview Mode Links will not work in preview mode

This Week in Cardiology

Nov 18, 2022

AHA 2022, Part 2: IRONMAN, ECMO-CS, CTS-AMI, and PROGRESSIVE AF are the trials John Mandrola, MD, reviews in this week’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. Pushback on PROMINENT

Zimerman Thread:


IRONMAN Galvanizes Case for IV Iron Repletion in Heart Failure

Is Iron Replacement in Heart Failure Worth the Trouble?

- Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial


Avoid Routine Early ECMO in Severe Cardiogenic Shock: ECMO-CS

- Extracorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock: Results of the ECMO-CS Randomized Clinical Trial

- Venoarterial Extracorporeal Membrane Oxygenation for Cardiogenic Shock and Cardiac Arrest


Chinese Herbal Medicine May Offer Benefits in STEMI: CTS-AMI


First-Line AF Ablation Cuts Risk of Progression vs Drug Therapy

Role of Ablation Type and Risk Factors in Paroxysmal AF: PROGRESSIVE-AF Interview

- Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation

- Progression of Atrial Fibrillation after Cryoablation or Drug Therapy

- Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact